TruDiagnostic is an Aging Diagnostics & Biomarkers company founded in 2020 and based in Lexington, United States.
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.

NAD+ supplementation and cellular health metrics remain dominant themes in longevity consumer trends.
TruAge is TruDiagnostic's flagship DNA-methylation test, analyzing more than 900,000 methylation markers from a blood sample to estimate biological age and a suite of aging-related metrics. It surfaces multiple validated epigenetic clocks alongside the company's own next-generation algorithms, giving clinicians and consumers a longitudinal readout of how fast a person is aging and how interventions affect that trajectory. The test is run in TruDiagnostic's CLIA-certified Lexington lab and is widely used in longevity research and personalized-medicine practices.
TruDiagnostic offers a portfolio of advanced epigenetic biomarkers: OMICmAge, a multi-omics clock developed with Harvard that integrates proteomic and metabolomic signals into methylation-based age estimates; DunedinPACE, a Duke-licensed blood biomarker of the pace of aging; and Systems Age, which decomposes biological age into organ- and system-specific scores. Together these algorithms let researchers and clinicians characterize not just overall biological age but where in the body aging is accelerating, supporting targeted intervention and study design.